NEW YORK (Reuters) - The business model of Valeant Pharmaceuticals International Inc , target of a securities investigation and under scrutiny for its pricing and accounting practices, "was based on leverage and financial engineering," fund manager Bill Gross of Janus Capital Group Inc said Tuesday.
Read more
No comments:
Post a Comment